» Articles » PMID: 37993809

Isolation of Virulent Phages Against Multidrug-resistant Acinetobacter Baumannii Recovered from Inanimate Objects of Jimma Medical Center, Southwest Ethiopia

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2023 Nov 22
PMID 37993809
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Because of the multidrug resistance features of Acinetobacter baumannii, endurance to diverse conditions, and causing health fatalities in healthcare settings, the global health system is looking for the development of new antimicrobials for such bacteria. As the new antimicrobial drugs pipeline is running dry, it is imperative to look for eco-friendly bio-control strategies. In this regard, phages are one to combat the biofilm producer and MDR A. baumannii. Thus, the study aimed to isolate and examine the role of phages against biofilm producers and MDR A. baumannii from inanimate objects at Jimma Medical Center (JMC), Ethiopia.

Method: Institution-based cross-sectional study was conducted from June to November 2019. A total of 309 swab samples were collected from inanimate objects and the environment in JMC. Isolation of A. baumannii, antimicrobial susceptibility testing, and biofilm detection were carried out according to standard protocol. Kirby Bauer disk diffusion and microliter plate were methods for AST and biofilm detection, respectively. Specific phage was isolated and characterized from sewage at JMC compound. The data were analyzed by SPSS version 25.0, and chi-square (X) cross-tabulation was used to determine the correlation of variables. A P-value of < 0.05 was considered a statistically significant association.

Result: A. baumannii from inanimate objects and surfaces of different environments at JMC was detected in 6.5% of the samples. From 20 of the isolates, 85% were biofilm producers, and 60% were MDR. The lytic phage isolated specifically against A. baumannii was found host specific, and thermally stable ranging from 10-50°C. The phage was active against 42% of MDR A. baumannii, 40% of both biofilm-producing and MDR A. baumannii (MDRAB), and 35.3% of the biofilm-producing isolates.

Conclusion: The good activity of phages towards MDRAB isolates, its biofilm degradation capability, thermal stability, and host specificity in our study encourages viewing the potential use of phages as a bio-control agent besides the routine cleansing agents. Therefore, we recommend isolation of specific phages in the eradication of MDRAB from health facilities with additional efforts to characterize in detail and assess their efficacy in animal models.

Citing Articles

Biofilm Resilience: Molecular Mechanisms Driving Antibiotic Resistance in Clinical Contexts.

Almatroudi A Biology (Basel). 2025; 14(2).

PMID: 40001933 PMC: 11852148. DOI: 10.3390/biology14020165.


Comprehensive Approaches to Combatting Biofilms: From Biofilm Structure to Phage-Based Therapies.

Grygiel I, Bajrak O, Wojcicki M, Krusiec K, Jonczyk-Matysiak E, Gorski A Antibiotics (Basel). 2024; 13(11).

PMID: 39596757 PMC: 11591314. DOI: 10.3390/antibiotics13111064.

References
1.
Vazquez-Lopez R, Solano-Galvez S, Juarez Vignon-Whaley J, Abello Vaamonde J, Padro Alonzo L, Rivera Resendiz A . Resistance: A Real Challenge for Clinicians. Antibiotics (Basel). 2020; 9(4). PMC: 7235888. DOI: 10.3390/antibiotics9040205. View

2.
Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Cirkovic I . Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS. 2007; 115(8):891-9. DOI: 10.1111/j.1600-0463.2007.apm_630.x. View

3.
Eze E, Chenia H, El Zowalaty M . biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect Drug Resist. 2018; 11:2277-2299. PMC: 6245380. DOI: 10.2147/IDR.S169894. View

4.
Pritsch M, Zeynudin A, Messerer M, Baumer S, Liegl G, Schubert S . First report on bla -producing Acinetobacter baumannii in three clinical isolates from Ethiopia. BMC Infect Dis. 2017; 17(1):180. PMC: 5333390. DOI: 10.1186/s12879-017-2289-9. View

5.
Dancer S . How do we assess hospital cleaning? A proposal for microbiological standards for surface hygiene in hospitals. J Hosp Infect. 2004; 56(1):10-5. PMC: 7134512. DOI: 10.1016/j.jhin.2003.09.017. View